DDInter1001 DDInter782
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Ixabepilone {u} (Compound) treats {v} (Disease) breast cancer
Ixabepilone {u} (Compound) binds {v} (Gene) TUBB3
Ixabepilone {u} (Compound) is included by {v} (Pharmacologic Class) Microtubule Inhibition
Ixabepilone {u} (Compound) causes {v} (Side Effect) Dehydration
Ixabepilone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capecitabine
Ixabepilone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Imatinib
Ixabepilone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troleandomycin
Ixabepilone {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Ixabepilone {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Ixabepilone (Compound) treats breast cancer (Disease)
Ixabepilone (Compound) binds TUBB3 (Gene)
Ixabepilone (Compound) is included by Microtubule Inhibition (Pharmacologic Class)
Ixabepilone (Compound) causes Dehydration (Side Effect)
Ixabepilone may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Ixabepilone may lead to a major life threatening interaction when taken with Clozapine
Ixabepilone may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated